https://doi.org/10.55788/6fcade78
PML is a rare, devastating, and often fatal demyelinating disease of the central nervous system caused by the JCPyV. Risk groups are severely immunosuppressed patients, such as transplant recipients, HIV/aids patients, and patients with multiple sclerosis using specific medications, and the increasing use of immunosuppressive treatments in the past years has caused a rise in the prevalence of PML cases. There is currently no treatment for PML.
First author Dr George Ambalathingal (QIMR Berghofer Medical Research Institute, Australia) emphasised T-cell therapy has been highlighted as a promising approach for PML treatment over the past decade, especially JCPyV-specific or BK polyomavirus (BKPyV)-specific T-cell products [1]. In collaboration with Cellevolve, Dr Ambalathingal's group developed a novel allogeneic, off-the-shelf immunotherapy, CE-VST01-JC, consisting of JCPyV-specific T-cells from healthy donors. These T-cells were expanded using a targeted, highly curated peptide mix, consisting of 36 JCPyV-specific peptides derived from all 5 antigens of JCPyV (i.e., LT, ST, VP1, VP2, and VP3), covering 32 class I and class II human leukocyte antigen (HLA) alleles. The peptide mix was extensively assessed for JCPyV-specificity, allogenicity, and functionally and phenotypically characterised. The results showed high specificity and more immunogenic precision with a minimised risk of graft-versus-host disease (GvHD). The in vitro characterisation indicated that CE-VST01-JC contains highly potent JCPyV-specific T-cells with stem-cell-like memory T-cells, lacking any off-target reactivity.
The clinical safety and efficacy of CE-VST01-JC will be evaluated in the multicentre, randomised, double-blind, phase 2 study ASCEND-JC (NCT05541549), with an adaptive design (see Figure). The FDA recently approved the trial, which should start in late 2023 or early 2024. Up to 60 participants will be randomised 2:1 to 4 infusions of 100 million cells of HLA-matched JCPyV-specific T-cells each, or placebo. Dr Ambalathingal explained it would be the largest trial of a PML treatment ever. Meanwhile, both CE-VST01-JC and T-cell treatments for the BK-virus (CE-VST01-BK) have become available in Australia for compassionate use. He noted that the results in 12 participants were very promising and encouraging.
Figure: Design of ASCEND-JC, a global pivotal phase 2 trial [1]
HLA, human leukocyte antigen; VST, CE-VST01-JC; LFTU, rate of lost to follow up.
- Ambalathingal GR, et al. CE-VST01-JC: A novel allogeneic T-cell based immunotherapy for the treatment of progressive multifocal leukoencephalopathy (PML). PL4.001, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Original antigenic sin influences humoral immune response to SARS-CoV-2 »
« Letter from the Editor Next Article
Original antigenic sin influences humoral immune response to SARS-CoV-2 »
Table of Contents: AAN 2023
Featured articles
Letter from the Editor
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy
Infectious Diseases
Allogenic T-cell-based immunotherapy for PML in development
Cognitive Impairment and Dementia
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Headache and Migraine
Lecture on migraine: from the prodromal phase to future paradigm shifts
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine
A vaccine as a potentially safe and effective immunotherapy against CGRP
Multiple Sclerosis
Teriflunomide prevents conversion to MS in patients with RIS
Gold nanocrystals may be effective as adjunctive MS therapy
Muscle and Neuro-Muscular Disorders
First-ever ALS platform trial reports on outcomes of 4 treatments
Pridopidine for Huntington’s disease fails to meet the primary endpoint
Parkinson's Disease
Continuous levodopa/carbidopa infusion shows favourable safety and efficacy
Unilateral right STN-DBS improves verbal fluency
Stroke
Harnessing the microbiome as a possible stroke treatment
Patients with a large core infarct benefit from thrombectomy
Miscellaneous
Artificial intelligence applications in neurology: seize the moment
Spinal cord stimulation eases painful diabetic neuropathy
EVT improves functional outcomes in Chinese patients with BAO
Severe sleep apnoea associated with white matter hyperintensities
Related Articles
October 29, 2020
Physical activity improves AHI in sleep apnoea patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com